Fig. 1: Fluorescent images of P-LPK binding to human CRC cells and cancer tissues.
From: Anti-tumor effects of P-LPK-CPT, a peptide-camptothecin conjugate, in colorectal cancer
a The FITC-P-LPK conjugate emitted stronger green fluorescence in CRC cells than normal NCM460 cells. Bar,10 μm. b The FITC-P-LPK conjugate selectively binds to CRC tissues (HE staining) Bar, 50 μm. c, d The fluorescence intensity of the P-LPK peptide in CRC cells (c) and tissues (d) was significantly higher than that of normal cells and tissues (n = 3, means ± SD, NCM460: P-CON vs P-LPK, p = 0.9385; Colo320HSR: P-CON vs P-LPK, p < 0.0001; HCT116: P-CON vs P-LPK, p < 0.0001; LoVo: P-CON vs P-LPK, p = 0.0219; Adjacent normal tissues: P-CON vs P-LPK, p = 0.9934;Colon cancer tissues: P-CON vs P-LPK, p < 0.0001) (*p < 0.05, ****p < 0.0001). e The binding site of the P-LPK peptide in HCT116 cells was investigated after labeling the peptide with Rhodamine. Bar, 25 μm.
